Medications for Appetite Stimulation in Anorexia

Context-Specific Recommendations

The American College of Physicians recommends megestrol acetate (400-800 mg/day) as the most effective first-line pharmacological appetite stimulant for cancer-related anorexia, with approximately 25% of patients experiencing improved appetite and 8% achieving modest weight gain 1, 2
The British Journal of Cancer suggests that megestrol acetate at 160-480 mg/day is the optimal dose range, with 160 mg/day being the minimum effective dose, and doses above 480 mg/day showing no additional efficacy 3, 4
The National Comprehensive Cancer Network warns that megestrol acetate carries a risk of thromboembolic events in 1 in 6 patients, with mortality risk in 1 in 23 patients, and fluid retention is a common adverse effect 2
The American Society for Parenteral and Enteral Nutrition recommends corticosteroids (dexamethasone 2-8 mg/day) as an alternative option when megestrol acetate fails or is contraindicated, providing rapid onset of appetite stimulation but with serious adverse effects including muscle wasting, insulin resistance, and infections 5, 1
The European Society for Clinical Nutrition and Metabolism suggests that medroxyprogesterone acetate (MPA) at minimum 200 mg/day increases appetite significantly, though weight gain effects are less consistent than megestrol acetate 3, 4

The American Academy of Hospice and Palliative Medicine notes that cannabinoids (dronabinol 2.5-7.5 mg every 4 hours as needed) have limited evidence compared to megestrol acetate, but may benefit select patients with chemosensory alterations, with caution due to risk of delirium in elderly patients 2

The National Institute for Health and Care Excellence advises that cyproheptadine may have modest benefit but adverse effects limit its use, and hydrazine sulphate is not an appetite stimulant 3, 4
The American Heart Association contraindicates bupropion as it consistently promotes weight loss 6

The American Geriatrics Society recommends that appetite stimulants should be used in combination with or after failure of dietetic and oral nutritional management, and provide oral nutritional supplements when food intake is 50-75% of usual intake 3, 4, 1
The European Society of Clinical Nutrition and Metabolism emphasizes the importance of regular reassessment to evaluate benefit versus harm, and lower starting doses should be used for elderly patients with close monitoring for sedation and thromboembolic events 1, 6